Speaking at a conference this morning, Pfizer CEO Albert Bourla suggested that Metsera’s therapies could begin hitting the ...
Unpredictable communication and a lack of transparency are eroding the industry’s and the public’s trust. The FDA, experts ...
Korro Bio is moving back to square one as a preclinical biotech after the failure of KRRO-110 in alpha-1 antitrypsin ...
The decision to pause dapiglutide will help Zealand focus investment into assets that have “the greatest potential for ...
In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial ...
Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes ...
The plausible mechanism pathway "could accelerate gene therapy/editing development but additional clarity [is] needed," ...
The back-heavy deal includes a $5 million upfront payment for two novel T cell engagers, though the companies have yet to ...
In this episode presented by Slone Partners, Leslie Loveless, Co-CEO and Managing Partner discusses how hiring and the ...
One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...
While most BioSpace LinkedIn poll respondents believe the job market won’t improve until at least 2027, two industry experts ...
Nearly two dozen life sciences companies that were awarded Massachusetts tax incentives to create and retain about 1,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback